SYK Related Analyst Ratings
-
SunTrust Robinson Humphrey Downgrades Stryker (SYK) to Reduce
-
Credit Suisse Downgrades Stryker (SYK) to Neutral
-
UBS Downgrades Stryker (SYK) to Neutral
-
Mizuho Securities Downgrades Stryker (SYK) to Neutral
-
Standpoint Research Downgrades Stryker (SYK) to Hold
-
SunTrust Robinson Humphrey Starts Stryker (SYK) at Neutral
-
Northland Securities Starts Stryker (SYK) at Market Perform
-
Oppenheimer Downgrades Stryker (SYK) to Perform
-
JMP Securities Starts Stryker (SYK) at Market Perform
-
Brean Murray Carret & Co. Starts Stryker (SYK) at Hold, Sees Limited Upside
-
Barclays on U.S Medical Supplies and Devices: Weekly Insight and Observations (SYK, MDT)
-
Canaccord Genuity Reiterates a 'Buy' on Stryker (SYK); Positive Analyst Day
-
Jefferies Maintains a 'Hold' on Stryker (SYK); Medtech Debate at Analyst Meeting
-
Barclays Maintains an 'Equalweight' on Stryker (SYK); Q&A Ahead of Analyst Day
-
Wells Fargo Maintains an 'Outperform' on Stryker (SYK); The New CEO Is...
-
Piper Jaffray Downgrades Stryker (SYK) to Neutral
-
Stryker's (SYK) Modular Hip Recall Could Impact Wright Medical (WMGI) - Analyst
-
Cantor Fitzgerald Starts Stryker (SYK) at Hold; M&A Strategy Strong, But Waiting For Better Entry
-
Rodman & Renshaw Cuts Stryker (SYK) to Market Perform
-
Credit Suisse Starts Stryker (SYK) at Outperform
-
Wells Fargo Starts Stryker (SYK) at Outperform, Sets $62-$63 Valuation Range
-
Stryker (SYK) Shares Edge Lower as Lazard Cuts to Neutral
-
Wellington Shields Downgrades Stryker (SYK) to Gradually Accumulate
-
Canaccord Genuity Reiterates a 'Buy' on Stryker (SYK); CEO Abruptly Departs; Underlying Business Solid
-
BMO Capital Downgrades Stryker (SYK) to Market Perform
-
Canaccord Genuity Reiterates a 'Buy' on Stryker (SYK); MedSurg to the Rescue (Again), Recon Weak Industry-wide
-
Jefferies Cuts Numbers On Stryker (SYK) After Q4 Results
-
Canaccord Genuity Q4 Ortho Preview: Comments on ATEC, BMTI, EXAC, IART, RTIX, SYK, TSON & ZMH
-
Bernstein Downgrades Stryker (SYK) to Market Perform
-
Citi Downgrades Stryker (SYK) to Neutral, Reaffirms $55 Price Target
-
Kaufman Bros. on Medical Technology - Keeping Things Simple as We Enter 2012
-
Goldman Sachs Downgrades Stryker (SYK) to Neutral
-
Standpoint Research Downgrades Medtronic, Inc. (MDT) to Hold; Reducing Exposure
-
Barclays on Medical Supplies & Devices: Weekly Insights & Observations: November 28, 2011
-
Goldman Sachs Lifts Numbers On Stryker (SYK)
-
Barclays Maintains an 'Equalweight' on Stryker (SYK); September Quarter 10Q Review
-
Barclays Maintains an 'Equalweight' on Stryker (SYK); Good Quarter Given Weak Backdrop
-
UBS Maintains a 'Buy' on Stryker (SYK); Seeing the Forest
-
Canaccord Genuity Reiterates a 'Buy' on Stryker (SYK); New Hip Product Cycle Drives Recon Stabilization; MedSurg Keeps Chugging
-
BofA/Merrill Lynch Upgrades Stryker (SYK) to Buy
-
Deutsche Bank Cuts Price Target In MedTech
-
Barclays on Medical Supplies & Devices: Unchanged Ortho Market Dynamics
-
JPMorgan Upgrades BAX, SYK to Overweight, BSX to Neutral, Downgrades ZMH, ABT to Neutral
-
Citi Cuts Smith & Nephew (SNN) from Buy to Sell; Considers Multiple Issues
-
Citi Upgrades Stryker (SYK) to Buy
-
Kaufman Bros. Starts Stryker (SYK) at Buy, Continues to See Growth
-
Deutsche Bank Upgrades Stryker (SYK) to Buy; Quality Well-Diversified Company With a Sound Strategy
-
Goldman Sachs Adjusts Price Targets in Med Tech (COV) (EW) (ISRG) (more...)
-
Lazard Capital Upgrades Stryker (SYK) to Buy
-
Rodman & Renshaw Upgrades Stryker (SYK) to Market Outperform
Back to SYK Stock Lookup
